Epitalon
PeptideEpitalon (Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. Developed from over 35 years of Russian research on pineal gland extracts, it may support cellular longevity and regulate melatonin production. Note: Epitalon is a research peptide not approved by the FDA for human use and is not available as a regulated pharmaceutical in most countries.
Quick Answer
What it is
Epitalon (Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. Developed from over 35 years of Russian research on pineal gland extracts, it may support cellular longevity and regulate melatonin production.
Key findings
- Grade C: Oxidative Stress
- Grade C: Sleep Quality
- Grade C: Telomerase Activity (Aging & Longevity)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Epitalon
Quick Facts: Epitalon
- Best Evidence:Grade C
- Conditions Studied:4
- Research Outcomes:20
- Key Effect:Aging & Longevity
Detailed Outcomes
Evidence by Condition
Research Citations (57)
Related Peptides
CJC-1295
Peptide2 shared conditions · 10 outcomes
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with modifications to extend its biological half-life. Developed by ConjuChem Biotechnologies, it exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) which binds to albumin for an extended half-life of 6-8 days, and Modified GRF (1-29) without DAC with a half-life of approximately 30 minutes. Clinical trials demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults. Development was discontinued after Phase II trials, and it remains an investigational compound not approved by the FDA.
Thymosin Alpha-1
Peptide1 shared condition · 21 outcomes
Thymosin Alpha-1 (Tα1) is a 28-amino acid immunomodulatory peptide originally isolated from thymic tissue. It enhances T-cell function, modulates innate and adaptive immune responses, and has been approved in over 35 countries for treatment of chronic hepatitis B and as an immune adjuvant. Clinical research supports its use in viral hepatitis, sepsis, and as adjunctive cancer therapy, with a favorable safety profile across numerous trials.
MOTS-c
Peptide1 shared condition · 27 outcomes
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene. Discovered in 2015, it regulates metabolic homeostasis, insulin sensitivity, and has been shown to mimic some beneficial effects of exercise. MOTS-c levels naturally decline with age, and the peptide is being studied for age-related metabolic diseases.